Kymera Therapeutics Outlines Key 2026 Objectives and Strategy to Advance Industry Leading Portfolio of Oral Immunology Programs
Kymera Therapeutics, Inc. (KYMR)
Company Research
Source: GlobeNewswire
KT-621 BROADEN2 Phase 2b trial in AD ongoing, with data expected by mid-2027 KT-621 BREADTH Phase 2b trial in asthma initiated, with data expected in late-2027 KT-579 Phase 1 HV clinical trial expected to start in 1Q26, with data expected in 2H26 Advancing at least one new development candidate towards IND for a first-in-class, oral immunology program in 2026 Well-capitalized with $1.6 billion1 in cash and runway into 2029 Kymera to present its 2026 objectives at the J.P. Morgan 44th Annual Healthcare Conference today at 9:00 a.m. PT/12:00 p.m. ET WATERTOWN, Mass., Jan. 13, 2026 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced its anticipated 2026 preclinical and clinical milestones across its industry leading oral immunology pipeline. “Kymera enters 2026 from a position of exceptional strength, driven by signif
Show less
Read more
Impact Snapshot
Event Time:
KYMR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
KYMR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
KYMR alerts
High impacting Kymera Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
KYMR
News
- Kymera Therapeutics (KYMR) Upgraded to Buy: Here's Why [Yahoo! Finance]Yahoo! Finance
- Is Kymera Therapeutics (KYMR) Balancing Pipeline Ambition and Execution Risk After New KT-621 Milestone? [Yahoo! Finance]Yahoo! Finance
- Kymera Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 13GlobeNewswire
- Kymera Therapeutics (NASDAQ:KYMR) had its "buy" rating reaffirmed by analysts at B. Riley.MarketBeat
- Kymera Therapeutics (NASDAQ:KYMR) had its "outperform" rating reaffirmed by analysts at Royal Bank Of Canada.MarketBeat
KYMR
Earnings
- 11/4/25 - Miss
KYMR
Sec Filings
- 1/13/26 - Form 8-K
- 1/8/26 - Form SCHEDULE
- 1/6/26 - Form 4
- KYMR's page on the SEC website